Eledon Pharmaceuticals (ELDN) vs PepGen (PEPG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Eledon Pharmaceuticals (ELDN) has outperformed PepGen (PEPG) over the past year, losing 15.7% versus a loss of 51.1%. Eledon Pharmaceuticals is the larger company by market cap ($201.5 million vs $181.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELDN | PEPG |
|---|---|---|
| Share price | $2.48 | $2.62 |
| Market cap | $201.53M | $181.22M |
| 1-day change | +2.48% | +10.08% |
| YTD return | +60.26% | -63.44% |
| 1-year return | -15.68% | -51.13% |
| 5-year return | -57.02% | — |
| EPS (TTM) | $-0.90 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.60 | $7.80 |
| 52-week low | $1.35 | $1.31 |
| Distance from 52-week high | -46.09% | -66.41% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +262.90% | +288.93% |
| Average volume | 935.08K | 946.80K |
| Shares outstanding | 81.26M | 69.17M |
| Employees | 33 | 57 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ELDN has outperformed PEPG by 35.4 percentage points over the past year.
About Eledon Pharmaceuticals
ELDN stock →Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
ELDN vs PEPG FAQ
Which is bigger, Eledon Pharmaceuticals or PepGen?
Eledon Pharmaceuticals (ELDN) is larger, with a market capitalization of $201.53M compared with $181.22M for PepGen (PEPG).
Which stock has performed better over the past year, ELDN or PEPG?
ELDN returned -15.68% over the past 12 months, compared with -51.13% for PEPG (price return, excluding dividends). Past performance does not predict future results.
Are Eledon Pharmaceuticals and PepGen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.